We are living in an unprecedented era of rapid medical innovation in the face of COVID-19. The speed of development for devices and diagnostics has been driven by the urgency of the pandemic resulting in enhanced public-private collaboration, access to funding, and a reduced regulatory burden.
While the pace of medical innovation today can be seen as an inspiring silver lining, it also highlights the lack of that speed over the past 20 years. When the dust settles and COVID-19 is behind us (and it will be behind us), I find myself asking the following questions:
- What lessons will we have learned to keep the positive momentum going into the future?
- What will happen when our public-private collaborations, access to funding, and regulatory pathways to commercialization resume to the status quo?
- Will the pace of medical innovation also wind back down to the pre-COVID era?